308 related articles for article (PubMed ID: 19737048)
1. Saquinavir, the pioneer antiretroviral protease inhibitor.
la Porte CJ
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
[TBL] [Abstract][Full Text] [Related]
2. Saquinavir/Ritonavir: its evolution and current treatment role.
O'Brien WA
AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
[TBL] [Abstract][Full Text] [Related]
3. Saquinavir (Fortovase or Invirase).
Res Initiat Treat Action; 2000 Mar; 6(1):24-5. PubMed ID: 11708182
[No Abstract] [Full Text] [Related]
4. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
Lindsey JC; Malee KM; Brouwers P; Hughes MD;
Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
[TBL] [Abstract][Full Text] [Related]
5. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
[No Abstract] [Full Text] [Related]
6. [A further option in PI therapy. Approval of a new protease inhibitor in the USA].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():30. PubMed ID: 16385868
[No Abstract] [Full Text] [Related]
7. Saquinavir in the management of HIV infection.
Moyle G
Br J Hosp Med; 1997 Jun 4-17; 57(11):560-4. PubMed ID: 9307673
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.
van der Lugt J; Colbers A; Molto J; Hawkins D; van der Ende M; Vogel M; Wyen C; Schutz M; Koopmans P; Ruxrungtham K; Richter C; Burger D;
Antivir Ther; 2009; 14(3):443-50. PubMed ID: 19474478
[TBL] [Abstract][Full Text] [Related]
10. Management of HIV infection in Nigeria with zalcitabine in combination with saquinavir mesylate: preliminary findings.
Akinsete I; Njoku OS; Okanny CC; Chukwuani CM; Akanmu AS;
West Afr J Med; 2000; 19(4):265-8. PubMed ID: 11391837
[TBL] [Abstract][Full Text] [Related]
11. New study of Fortovase (Saquinavir) in women.
WORLD; 1998 Nov; (No 91):4. PubMed ID: 11365973
[TBL] [Abstract][Full Text] [Related]
12. No tease this time--pros and cons of a long-awaited anti-HIV drug.
Chang HE
Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
[TBL] [Abstract][Full Text] [Related]
13. Are men and women really different?
Res Initiat Treat Action; 1998 Dec; 4(7):13. PubMed ID: 11366080
[TBL] [Abstract][Full Text] [Related]
14. Do women respond differently to HIV therapy than men?
Newsline People AIDS Coalit N Y; 1998 Dec; ():31. PubMed ID: 11367087
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV agents. Atazanavir and saquinavir.
TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
[No Abstract] [Full Text] [Related]
16. Anti-HIV agents. Starting therapy with saquinavir.
TreatmentUpdate; 2007 Jan; 19(1):8-9. PubMed ID: 17393566
[No Abstract] [Full Text] [Related]
17. New formulation of saquinavir (Fortovase) is more effective.
Tam CW
Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.
Gill MJ
AIDS; 1998 Jul; 12(11):1400-2. PubMed ID: 9708428
[No Abstract] [Full Text] [Related]
19. Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Redmond AM; Skinner-Adams T; Andrews KT; Gardiner DL; Ray J; Kelly M; McCarthy JS
AIDS; 2007 Mar; 21(6):763-5. PubMed ID: 17413699
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV agents. Promising results from a saquinavir study.
TreatmentUpdate; 2007 Jan; 19(1):9-10. PubMed ID: 17390482
[No Abstract] [Full Text] [Related]
[Next] [New Search]
